Up-front Chemotherapy

PreclinicalSmall molecule

UUniversity of Milan

Up-front Chemotherapy is one of 46 small molecule programs targeting Glioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

GliomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Camptosar

Pfizer

Phase 2

5 6

Verzenio

Eli Lilly

Phase 2

3 7

Lynparza

AstraZeneca

Phase 2

3 8

Imfinzi

AstraZeneca

Phase 2

1 9

Lenvima

Eisai

Phase 2

1 10

Oncovin

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Glioma

NCT06381726

Clinical

Trials by Indication[1]

Glioma1 trial

Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life

Recruiting·UUniversity of Milan·N/A·NCT06381726·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Up-front Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Up-front Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Up-front Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Milan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Milan

Up-front Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Glioma1 trial

References

Drug Info

Quick Facts

Related News